|Bid||4.92 x 700|
|Ask||4.93 x 700|
|Day's range||4.83 - 5.01|
|52-week range||3.95 - 7.39|
|PE ratio (TTM)||N/A|
|Earnings date||2 May 2018 - 7 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.83|
BioCryst Pharmaceuticals, Inc. and Idera Pharmaceuticals, Inc. today jointly announced that they have each rescheduled their respective Special Meetings of Stockholders to vote on the proposed merger of BioCryst and Idera to July 10, 2018 at 10:00 AM ET.
BioCryst Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the pending merger of BioCryst and Idera.
The Durham, North Carolina-based company said it had a loss of 20 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...